{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T17:06:58Z","timestamp":1767460018217,"version":"3.48.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Lid margin collarettes are a distinct clinical finding and their association with meibomian gland dysfunction (MGD) and dry eye symptoms and signs remains uncertain. We leverage the large cohort of subjects in the Dry Eye Assessment and Management (DREAM) study data to elucidate collarettes\u2019 impact on dry eye disease (DED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>We performed secondary analysis of DREAM study data, a multicentre, double-blinded clinical trial evaluating omega-3 supplementation in patients with moderate-to-severe DED. DED symptoms (Ocular Surface Disease Index [OSDI] and Ocular Discomfort) and signs (conjunctival staining, corneal staining, tear break-up time (TBUT), Schirmer test, MGD grade) were compared by collarette presence and severity. Data from all visits (baseline, months 3, 6, 12) were assessed and adjusted for demographics and baseline comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1070 eyes at baseline, 65.3% had no collarettes, 28.0% had 1\u20135, and 6.6% had 6\u201320. Over the 1\u2009year period of the study, 67% of eyes had no change in collarette severity, while 19% had increased severity and 14% had decreased severity. Collarettes were more common in Whites (82.1% vs 69.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), non-Hispanics (92.3% vs 83.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), and those with facial rosacea (25.0% vs 17.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05). Multivariate analysis showed collarettes were associated with increased corneal staining (5.06 vs 4.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), decreased TBUT (3.24 vs 3.54\u2009s,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), decreased Schirmer test (7.92 vs 8.63,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), more severe eyelid erythema (18.6% vs 12.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and higher composite DED sign severity (0.51 vs 0.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). However, they were not associated with conjunctival staining, MGD grade, or DED symptoms (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2265\u20090.30). Similar findings were observed in comparisons of collarette severity. Subjects with collarettes had lower tear levels of IL-1\u03b2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), IL-10 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), and INF-\u03b3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collarettes were common in patients with moderate-to-severe DED, and most do not progress over time. Although they were associated with worse ocular surface signs, notably eyelid erythema, no association was found with dry eye symptoms. Our results will help physicians counsel and guide the approach to treating dry eye patients with collarettes, and generate pilot data for tear film biomarker identification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04105-5","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:19:51Z","timestamp":1764087591000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between lid margin collarettes and dry eye disease severity in the Dry Eye Assessment and Management (DREAM) study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8037-6953","authenticated-orcid":false,"given":"Alexander E.","family":"Azar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliot N.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Augello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-0904","authenticated-orcid":false,"given":"Penny A.","family":"Asbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-4201","authenticated-orcid":false,"given":"Rony R.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Dry Eye Assessment and Management (DREAM) Study Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"4105_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00347-007-1608-8","volume":"104","author":"C Auw-Haedrich","year":"2007","unstructured":"Auw-Haedrich C, Reinhard T. Chronic blepharitis. pathogenesis, clinical features, and therapy. Ophthalmologe. 2007;104:817\u201326.","journal-title":"Ophthalmologe"},{"key":"4105_CR2","doi-asserted-by":"crossref","unstructured":"Ayres BD, Donnenfeld E, Farid M, Gaddie IB, Gupta PK, Holland E, et al. Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). Eye. 2023;37:3249\u201355.","DOI":"10.1038\/s41433-023-02500-4"},{"key":"4105_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/ICO.0000000000002911","volume":"41","author":"PP Shah","year":"2022","unstructured":"Shah PP, Stein RL, Perry HD. Update on the management of Demodex blepharitis. Cornea. 2022;41:934\u20139.","journal-title":"Cornea"},{"key":"4105_CR4","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/OPTH.S354692","volume":"16","author":"W Trattler","year":"2022","unstructured":"Trattler W, Karpecki P, Rapoport Y, Sadri E, Schachter S, Whitley WO, et al. The prevalence of demodex blepharitis in us eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153\u201364.","journal-title":"Clin Ophthalmol"},{"key":"4105_CR5","doi-asserted-by":"crossref","unstructured":"Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). Ophthalmology. 2023;130:1015\u201323.","DOI":"10.1016\/j.ophtha.2023.05.030"},{"key":"4105_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0039-6257(96)80064-6","volume":"40","author":"PJ Driver","year":"1996","unstructured":"Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343\u201367.","journal-title":"Surv Ophthalmol"},{"key":"4105_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/OPTO.S142708","volume":"10","author":"SR Fromstein","year":"2018","unstructured":"Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom. 2018;10:57\u201363.","journal-title":"Clin Optom"},{"key":"4105_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ACI.0b013e32833df9f4","volume":"10","author":"J Liu","year":"2010","unstructured":"Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10:505\u201310.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4105_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cct.2018.06.002","volume":"71","author":"PA Asbell","year":"2018","unstructured":"Asbell PA, Maguire MG, Peskin E, Bunya VY, Kuklinski EJ. Dry Eye Assessment and Management (DREAM(c)) study: study design and baseline characteristics. Contemp Clin Trials. 2018;71:70\u201379.","journal-title":"Contemp Clin Trials"},{"key":"4105_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","volume":"378","author":"PA Asbell","year":"2018","unstructured":"Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, Hardten DR, et al. n-3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378:1681\u201390.","journal-title":"N Engl J Med"},{"key":"4105_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/02713683.2022.2162088","volume":"48","author":"NS Roy","year":"2023","unstructured":"Roy NS, Wei Y, Ying GS, Maguire MG. and P.A. Asbell, association of tear cytokine concentrations with symptoms and signs of dry eye disease: baseline data from the Dry Eye Assessment and Management (DREAM) study. Curr Eye Res. 2023;48:339\u201347.","journal-title":"Curr Eye Res"},{"key":"4105_CR12","doi-asserted-by":"crossref","unstructured":"Zhao, C.S., Y. Chen, Y. Yu, G.S. Ying, and P.A. Asbell, longitudinal analysis of tear cytokine ratios in association with dry eye signs and symptoms in the Dry Eye Assessment and Management (DREAM) study. Curr Eye Res. 2025;50:124\u2013131.","DOI":"10.1080\/02713683.2024.2398113"},{"key":"4105_CR13","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1167\/iovs.13-12132","volume":"54","author":"Y Wei","year":"2013","unstructured":"Wei Y, Gadaria-Rathod N, Epstein S, Asbell P. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Investig Ophthalmol Vis Sci. 2013;54:8327\u201336.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4105_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/tvst.8.4.31","volume":"8","author":"NS Roy","year":"2019","unstructured":"Roy NS, Wei Y, Yu Y, Ying GS, Kuklinski E, Barry B, et al. Management study, conjunctival HLA-DR expression and its association with symptoms and signs in the dream study. Transl Vis Sci Technol. 2019;8:31.","journal-title":"Transl Vis Sci Technol"},{"key":"4105_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.ophtha.2021.03.030","volume":"128","author":"K Yu","year":"2021","unstructured":"Yu K, Bunya V, Maguire M, Asbell P, Ying GS. Systemic conditions associated with severity of dry eye signs and symptoms in the dry eye assessment and management study. Ophthalmology. 2021;128:1384\u201392.","journal-title":"Ophthalmology"},{"key":"4105_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/jocd.13150","volume":"19","author":"G Sarac","year":"2020","unstructured":"Sarac G, Cankaya C, Ozcan KN, Cenk H, Kapicioglu YK. Increased frequency of Demodex blepharitis in rosacea and facial demodicosis patients. J Cosmet Dermatol. 2020;19:1260\u20135.","journal-title":"J Cosmet Dermatol"},{"key":"4105_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/ICL.0000000000001003","volume":"49","author":"MK Rhee","year":"2023","unstructured":"Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal DK, Nichols KK, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49:311\u20138.","journal-title":"Eye Contact Lens"},{"key":"4105_CR18","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","volume":"80","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Callender VD, Baldwin HE, Desai SR, Rendon MI, Taylor SC. Global epidemiology and clinical spectrum of rosacea, highlighting skin of colour: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722\u20131729.e7.","journal-title":"J Am Acad Dermatol"},{"key":"4105_CR19","doi-asserted-by":"publisher","first-page":"e36021","DOI":"10.1016\/j.heliyon.2024.e36021","volume":"10","author":"AD Graham","year":"2024","unstructured":"Graham AD, Kothapalli T, Wang J, Ding J, Tse V, Asbell PA, et al. A machine learning approach to predicting dry eye-related signs, symptoms and diagnoses from meibography images. Heliyon. 2024;10:e36021.","journal-title":"Heliyon"},{"key":"4105_CR20","doi-asserted-by":"publisher","first-page":"833778","DOI":"10.3389\/fmed.2022.833778","volume":"9","author":"Y Hao","year":"2022","unstructured":"Hao Y, Zhang X, Bao J, Tian L, Jie Y. Demodex folliculorum Infestation in meibomian gland dysfunction-related dry eye patients. Front Med. 2022;9:833778.","journal-title":"Front Med"},{"key":"4105_CR21","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/ICL.0000000000000640","volume":"46","author":"T Ayyildiz","year":"2020","unstructured":"Ayyildiz T, Sezgin FM. The effect of ocular demodex colonization on schirmer test and osdi scores in newly diagnosed dry eye patients. Eye Contact Lens. 2020;46:S39\u2013s41.","journal-title":"Eye Contact Lens"},{"key":"4105_CR22","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/bjophthalmol-2017-310302","volume":"102","author":"L Liang","year":"2018","unstructured":"Liang L, Liu Y, Ding X, Ke H, Chen C, Tseng SCG. Significant correlation between meibomian gland dysfunction and keratitis in young patients with Demodex brevis infestation. Br J Ophthalmol. 2018;102:1098\u2013102.","journal-title":"Br J Ophthalmol"},{"key":"4105_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.4103\/IJO.IJO_2981_22","volume":"71","author":"NR Kumar","year":"2023","unstructured":"Kumar NR, Praveen M, Narasimhan R, Khamar P, D\u2019Souza S, Sinha-Roy A, et al. Tear biomarkers in dry eye disease: progress in the last decade. Indian J Ophthalmol. 2023;71:1190\u2013202.","journal-title":"Indian J Ophthalmol"},{"key":"4105_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18240\/ijo.2023.02.05","volume":"16","author":"YY Gao","year":"2023","unstructured":"Gao YY, Wang T, Jiang YT, Yang MJ, Lu XH, Zheng L, et al. Should ocular Demodex be checked and treated in refractory keratitis patients without blepharitis? Int J Ophthalmol. 2023;16:201\u20137.","journal-title":"Int J Ophthalmol"},{"key":"4105_CR25","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/ICO.0000000000000627","volume":"34","author":"CL Grosskreutz","year":"2015","unstructured":"Grosskreutz CL, Hockey HU, Serra D, Dryja TP. Dry eye signs and symptoms persist during systemic neutralization of IL-1\u03b2 by canakinumab or IL-17A by secukinumab. Cornea. 2015;34:1551\u20136.","journal-title":"Cornea"},{"key":"4105_CR26","doi-asserted-by":"crossref","unstructured":"Kak, G., M. Raza, and B.K. Tiwari. Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases. Biomol Concepts. 2018;9:64\u201379.","DOI":"10.1515\/bmc-2018-0007"},{"key":"4105_CR27","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-023-06281-0","volume":"262","author":"F Valvecchia","year":"2024","unstructured":"Valvecchia F, Greco L, Perrone F, Logioco C, Caride GG, Perrone L, et al. Topical ivermectin ointment treatment of Demodex blepharitis: a 6-year retrospective study. Graefe's Arch Clin Exp Ophthalmol. 2024;262:1281\u20138.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04105-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T17:02:05Z","timestamp":1767459725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04105-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4105"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04105-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}